NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Safety and Efficacy of Xalkori ROS1

Active Not RecruitingN/A

Sponsor: Pfizer

Conditions: Non-small Cell Lung Cancer

Interventions: crizotinib

Countries: Japan

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* patients with unresectable progressive/recurrent NSCLC who are naive to XALKORI and whose tumor is ROS1 gene positive

Exclusion Criteria:

* Patients with past history of hypersensitivity to any of the ingredients of XALKORI

Locations (1)

Tokyo, Japan